Difference between revisions of "Krishnathas 2017 Med Chem Comm"
Line 11: | Line 11: | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |area=Respiration, Pharmacology;toxicology | ||
|organism=Rat | |organism=Rat | ||
|tissues=Heart | |tissues=Heart | ||
Line 17: | Line 17: | ||
|topics=Inhibitor | |topics=Inhibitor | ||
|couplingstates=OXPHOS | |couplingstates=OXPHOS | ||
|pathways=N, NS | |pathways=N, S, NS | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
}} | }} |
Revision as of 13:49, 4 June 2018
Krishnathas R, Bonke E, Drรถse S, Zickermann V, Nasiri HR (2017) Identification of 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine as a novel, highly potent and specific inhibitor of mitochondrial complex I. Med Chem Comm 8:657-61. |
ยป [1]
Krishnathas R, Bonke E, Droese S, Zickermann V, Nasiri HR (2017) Med Chem Comm
Abstract: By probing the quinone substrate binding site of mitochondrial complex I with a focused set of quinazoline-based compounds, we identified substitution patterns as being critical for the observed inhibition. The structure activity relationship study also resulted in the discovery of the quinazoline 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine (EVP4593) as a highly potent inhibitor of the multisubunitmembrane protein. EVP4593 specifically and effectively reduces the mitochondrial complex I-dependent respiration with no effect on the respiratory chain complexes IIโIV. Similar to established Q-site inhibitors, EVP4593 elicits the release of reactive oxygen species at the flavin site of mitochondrial complex I. Recently, EVP4593 was nominated as a lead compound for the treatment of Huntingtons disease. Our results challenge the postulated primary mode-of-action of EVP4593 as an inhibitor of NF-ฮบB pathway activation and/or store-operated calcium influx.
โข Bioblast editor: Kandolf G โข O2k-Network Lab: DE Frankfurt Droese S
Labels: MiParea: Respiration, Pharmacology;toxicology
Organism: Rat
Tissue;cell: Heart
Preparation: Isolated mitochondria
Regulation: Inhibitor Coupling state: OXPHOS Pathway: N, S, NS HRR: Oxygraph-2k